Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The genodermatoses: candidate diseases for gene therapy.

J Uitto1, L Pulkkinen

  • 1Departments of Dermatology and Cutaneous Biology, Jefferson Medical College, and Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA. Jouni.Uitto@mail.tju.edu

Human Gene Therapy
|November 21, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mutation reports: epidermolysis bullosa simplex associated with severe mucous membrane involvement and novel mutations in the plectin gene.

The Journal of investigative dermatology·2000
Same author

Molecular genetics of Meesmann's corneal dystrophy: ancestral and novel mutations in keratin 12 (K12) and complete sequence of the human KRT12 gene.

Experimental eye research·2000
Same author

Compound heterozygosity for novel splice site mutations in the BPAG2/COL17A1 gene underlies generalized atrophic benign epidermolysis bullosa.

The Journal of investigative dermatology·2000
Same author

Cutaneous gene therapy. Principles and prospects.

Dermatologic clinics·2000
Same author

Combination of novel premature termination codon and glycine substitution mutations in COL7A1 leads to moderately severe recessive dystrophic epidermolysis bullosa.

The Journal of investigative dermatology·2000
Same author

A novel mutation in the helix termination motif of keratin K12 in a US family with Meesmann corneal dystrophy.

American journal of ophthalmology·1999
Same journal

Genome Editing for Familial Hemophagocytic Lymphohistiocytosis: Design Principles, Challenges, and Translational Perspectives.

Human gene therapy·2026
Same journal

Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration.

Human gene therapy·2026
Same journal

Hyperthermia-Enhanced Adeno-Associated Virus Gene Therapy: Mechanisms, Delivery Technologies, and Translational Potential.

Human gene therapy·2026
Same journal

Adeno-Associated Virus Gene Therapy Translation: Lessons from Early Regulatory Meetings.

Human gene therapy·2026
Same journal

In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>.

Human gene therapy·2026
Same journal

<i>In Vivo</i> Genome Editing Approach to Disrupt Hydroxyacid Oxidase 1 for the Treatment of Primary Hyperoxaluria Type 1.

Human gene therapy·2026
See all related articles

Gene therapy for genodermatoses shows promise, utilizing skin cells for treatment. Research focuses on genetic mutations and delivery systems for effective cutaneous gene therapy development.

Area of Science:

  • Genetics
  • Dermatology
  • Molecular Biology

Background:

  • Genodermatoses are heritable skin diseases with diverse clinical presentations.
  • Understanding genetic mutations is key to developing targeted therapies.
  • Skin's accessibility and cell culture suitability make it an ideal target for gene therapy.

Purpose of the Study:

  • To review the progress and strategic considerations for cutaneous gene therapy in genodermatoses.
  • To highlight the potential of gene therapy for heritable skin conditions.

Main Methods:

  • Review of genetic basis of genodermatoses.
  • Analysis of candidate gene/protein systems.
  • Evaluation of in vivo and ex vivo gene therapy approaches.
  • Consideration of gene replacement vs. gene repair strategies.

Related Experiment Videos

  • Assessment of various delivery systems for cutaneous gene therapy.

    • Main Results:

    • Significant advancements in understanding the genetic underpinnings of genodermatoses.
    • Identification of specific mutations providing a foundation for gene therapy development.
    • Skin cells (keratinocytes, fibroblasts) are suitable for ex vivo gene therapy.

    Conclusions:

    • Cutaneous gene therapy is a viable therapeutic strategy for genodermatoses.
    • Strategic choices in gene therapy (in vivo/ex vivo, repair/replacement, delivery) must be tailored to specific mutations and their molecular consequences.